Geron Corporation (NASDAQ:GERN) Given Average Recommendation of “Hold” by Analysts

Shares of Geron Corporation (NASDAQ:GERN) have been given a consensus recommendation of “Hold” by the six ratings firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $2.50.

Separately, Weiss Ratings cut Geron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd.

Institutional Trading of Geron

Large investors have recently made changes to their positions in the business. 55 North Private Wealth LLC bought a new stake in shares of Geron during the fourth quarter worth $29,000. Hsbc Holdings PLC bought a new stake in shares of Geron during the first quarter valued at approximately $33,000. LCM Capital Management Inc grew its stake in shares of Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the last quarter. Vistica Wealth Advisors LLC bought a new stake in shares of Geron during the fourth quarter valued at approximately $33,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 24,410 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Price Performance

Shares of Geron stock opened at $1.30 on Tuesday. The company has a current ratio of 6.78, a quick ratio of 4.96 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $833.98 million, a price-to-earnings ratio of -11.82 and a beta of 0.61. Geron has a 1-year low of $1.04 and a 1-year high of $2.01. The firm’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.45.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The firm had revenue of $51.84 million for the quarter, compared to analysts’ expectations of $50.59 million. Geron had a negative net margin of 35.48% and a negative return on equity of 23.31%. On average, equities analysts predict that Geron will post -0.02 earnings per share for the current fiscal year.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.